OBJECTIVES:
To describe the demographics, prescription drug utilization, medication adherence, and pharmacy costs for Medicare Advantage and Medicare Prescription Drug Plan members initiated on paliperidone palmitate (PALI-PALM), a long-acting antipsychotic for treating schizophrenia. METHODS: The Humana pharmacy claims database was used to identify Medicare Advantage and Medicare Prescription Drug Plan members with a pharmacy claim for PALI-PALM between September 1, 2009, and December 31, 2010 . Six-month preindex and postindex observation periods were used to assess medication utilization and medicationrelated costs for patients starting PALI-PALM. Medication possession ratio (MPR) for PALI-PALM was calculated using a fixed denominator of six months. RESULTS: Four hundred forty-one patients met the inclusion criteria. Mean (ϮSD) age was 46.9 (Ϯ12.6) years. Three hundred ninety-seven patients (90.0%) had a low-income subsidy (LIS), and 331 (75.1%) were dually eligible for Medicaid. Patients initiated on PALI-PALM received a mean of 1.9 (Ϯ1.0) unique antipsychotics during the preindex period. One hundred six patients (24%) who had initiated on PALI-PALM had received 3 or more antipsychotics during the preindex period. Antidepressant (56.9%), anticonvulsant (49.2%), and antiparkinsonism (39.0%) drugs were the most frequently observed nonantipsychotic mental health medications during the preindex period. Compared with the preindex period, use of benzodiazepines and nonbenzodiazepine anxiolytics decreased during the postindex period (benzodiazepines: 10.0% versus 7.3%; McNemar's test, pϭ0.034; nonbenzodiazepine anxiolytics: 12.5% versus 8.4%; McNemar's test, pϭ0.007). Two hundred forty-one patients (54.6%) displayed an MPR for PALI-PALM Ն0.80 during the 6-month postindex period. Analysis regarding medication-related costs will be presented in the poster. CONCLUSIONS: A majority of Medicare members who had initiated on PALI-PALM had a LIS and dual eligibility. Use of multiple antipsychotics during the preindex period was common among members initiated on PALI-PALM. We observed a re-duction in the use of benzodiazepines and nonbenzodiazepine anxiolytics among members receiving PALI-PALM.
PMH43 TREATMENT PATTERNS, RESOURCE UTILIZATION AND COSTS ASSOCIATED WITH GUANFACINE IMMEDIATE RELEASE VERSUS GUANFACINE EXTENDED RELEASE AMONG CHILDREN AND ADOLESCENTS WITH ATTENTION DEFICIT/ HYPERACTIVITY DISORDER (ADHD)
DiBello J 1 , Sikirica V 1 , Samuelson T 2 , Xie J 3 , He T 2 , Erder MH 1 1 Shire Development, LLC, Wayne, PA, USA, 2 Analysis Group, Inc., Boston, MA, USA, 3 Analysis Group, Inc., New York, NY, USA OBJECTIVES: Guanfacine is a centrally-acting alpha-2 adrenoceptor agonist available in immediate (GIR) and extended release (GXR) formulations. GIR is FDAapproved for hypertension, but is prescribed off-label for ADHD. GXR is US approved for symptomatic treatment of pediatric ADHD as mono-or adjunctive therapy. No outcomes study has compared the two formulations. This study descriptively compares treatment patterns, resource utilization, and cost, between children and adolescents with ADHD initiating treatment with GIR versus GXR. METHODS: Patients, aged 6-17, with Ն 1 claim for GIR or GXR from November 1, 2009-December 30, 2010 were identified from a large US commercial medical and pharmacy claims database. Patients had Ն 1 primary diagnosis of ADHD (ICD-9 codes: 314.00, 314.01) during the baseline period, no prior guanfacine use or hypertension diagnosis, and continuous eligibility for 6-months pre-and post-guanfacine initiation. Patient characteristics, resource utilization and costs were descriptively compared using Chi-square and student t-tests. ($4214 vs. $3934, pϭ0.41) were equivalent. CONCLUSIONS: Preliminary findings indicate children and adolescents may have higher rates of discontinuation/switching, and resource utilization when treated with GIR than GXR; costs were not different. Further adjusted analyses are underway comparing outcomes between the two drugs.
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PMH44 UTILITY IMPROVEMENTS FROM A DEPRESSION HOME SUPPORT PROGRAM FOR OLDER AFRICAN AMERICANS: RESULTS FROM THE BEAT THE BLUES TRIAL
Pizzi LT 1 , Jutkowitz E 1 , Law M 2 , Komura S 2 , Gitlin L 3 1 Thomas Jefferson University, Philadelphia, PA, USA, 2 Jefferson School of Pharmacy, Philadelphia, PA, USA, 3 Johns Hopkins University, Baltimore, MD, USA OBJECTIVES: While utility improvements from depression treatments have been studied, little research has examined utility improvements from non-pharmacological treatments in older minorities. The objective of this study was to measure utility improvements from Beat the Blues (BTB), a non-pharmacological program for older depressed African Americans in which licensed senior center social workers meet with participants at home for up to 10 sessions over 4 months to assess care needs, make referrals/linkages, provide depression education, instruct in stress reduction techniques, and use behavioral activation to identify goals and steps to achieve them. METHODS: Utility (EQ-5D) was measured in a single-blind parallel group randomized clinical trial comparing BTB to wait list control. Patients were enrolled between 2009 and 2010, were African American, age Ն 55, had positive screen for depression (PHQ-9Ն5), English speaking, and cognitively intact. EQ-5D was administered at T1 (baseline), T2 (4 months) and T3 (8 months). Participants receiving control at T1 were switched to BTB at T2 and followed to T3; participants receiving BTB at T1 were switched to observation at T2 and followed to T3 ("post-BTB"). RESULTS: EQ-5D sample sizes for the study groups were T1-T2: BTBϭ69; controlϭ66, and T2-T3: BTBϭ79; post-BTBϭ70. EQ-5D index values for BTB versus control at T1 were 0.5701 (0.20 SD) versus 0.5705 (0.21 SD) and improved to 0.6638 (0.22 SD) versus 0.6308 (0.20 SD) at T2 (T1-T2 within group improvements were 0.0937 and 0.0603 for BTB versus control). EQ-5D index in the post-BTB group held from T2-T3 (slight 0.0093 within group increase). Participants switched to BTB from control from T2-T3 showed improvement (0.0655 within group increase). CONCLUSIONS: BTB resulted in meaningful and sustained utility improvement, in the range of depression treatments previously studied. Findings inform discussions about health gains which can be expected from non-pharmacological treatments in depressed older, underserved African Americans.
PMH45 UTILITY SCORES ASSOCIATED WITH THE WORLD HEALTH ORGANISATION DRINKING RISK-LEVEL CLASSIFICATION IN ALCOHOL DEPENDENCE
In the context of comparative research, the World Health Organisation (WHO) proposed to categorise the risk for alcohol-related acute and chronic harm according to patients' average daily alcohol consumption. OBJECTIVES: To estimate utility scores associated with each category of the WHO drinking risk-level classification in patients with alcohol dependence (AD). METHODS: We used data from CONTROL, an observational cohort study including 143 AD patients from the Alcohol Treatment Center at Lausanne University Hospital, followed for 12 months. Average daily alcohol consumption was assessed monthly using the Timeline Follow-back method and patients were categorised according to the WHO drinking risk-level classification: abstinent, low, medium, high and very high. Other measures as sociodemographic characteristics and utility scores derived from the Eu-roQoL 5-Dimensions questionnaire (EQ-5D) were collected every three months. Mixed models for repeated measures were used to estimate mean utility scores associated with WHO drinking risk-level categories. RESULTS: A total of 143 patients were included and the 12-month follow-up permitting the assessment of 1318 person-months. At baseline the mean age of the patients was 44.6 (SD 11.8) and the majority of patients was male (63.6%). Using repeated measures analysis, utility scores decreased with increasing drinking levels, ranging from 0.80 in abstinent patients to 0.62 in patients with very high risk drinking level (pϽ0.0001). CONCLUSIONS: In this sample of patients with alcohol dependence undergoing specialized care, utility scores estimated from the EQ-5D appeared to substantially and consistently vary according to patients' WHO drinking level.
PMH46 EXAMINING THE DIFFERENCES BETWEEN PATIENTS TREATED FOR MAJOR DEPRESSIVE DISORDER COMPARED TO THOSE WHO DO NOT REALIZE THEY HAVE MAJOR DEPRESSIVE DISORDER
Gross HJ 1 , Vietri J 2 , Chapnick J 1 1 Kantar Health, Princeton, NJ, USA, 2 Kantar Health, New York, NY, USA OBJECTIVES: Major Depressive Disorder (MDD) has a profound negative impact on sufferers' lives. This analysis sought to identify differences in patient characteristics and outcomes associated with self-report of depression and use of prescription treatment within a positively-screened MDD population. METHODS: Data were taken from the US 2011 National Health and Wellness Survey (nϭ75,000), a crosssectional Internet-based survey representative of US adults. Patients with MDD were identified using the Patient Health Questionnaire (PHQ-9). Health-related quality of life (HRQoL) was assessed with the SF-12 Health Survey (SF-12v2), and activity impairment was measured with the Work Productivity and Activity Impairment questionnaire (WPAI). Comparisons between patient groups were made with chi-square tests for categorical variables and ANOVA for continuous variables. RESULTS: PHQ-9 scores identified MDD in 6.3% of respondents (nϭ4,720); 33.5% (nϭ1,583) reported depression and prescription treatment, 30.0% (nϭ1418) reported depression without prescription treatment, and 36.4% (nϭ1719) did not self-report depression. Compared to those who did not self-report depression, treated patients were more likely to have severe depression according to PHQ-9 scores (32.5% vs. 22.2%), had lower mental HRQoL (28.5 vs. 37.3), and more activity impairment (60.5% vs. 47.4%) (psϽ0.001); however, fewer treated patients visited the emergency room in the past 6 months (25.0% vs. 21.3%, pϽ0.001). Patients who did not report depression were more likely to have completed college (34.6% vs. 30.6%) and had higher incomes (37.6% with incomes over $50,000 vs. 32.4%), but were less likely to have insurance (70.5% vs. 80.6%), and those with insurance were less likely to have prescription drug coverage (60.2% vs. 74.4%) (psϽ0.001). CONCLUSIONS: Patients who had MDD according to PHQ-9 but did not report depression had less severe depression and a higher mental QoL than treated patients, but still had poor health outcomes. Less comprehensive insurance coverage may be a barrier in seeking treatment.
PMH47 WHAT MAKES PEOPLE GENERALLY SATISFIED WITH MENTAL HEALTH SERVICES?
Sohn M 1 , Barrett H 2 , Talbert J 1 1 University of Kentucky, Lexington, KY, USA, 2 KY Dept. for Behavioral Health, Developmental & Intellectual Disabilities, Frankfort, KY, USA OBJECTIVES: The purpose of this study is to identify factors that predict whether clients will respond that they were "generally satisfied" with services received from Kentucky Community Mental Health Centers (CMHCs) in 2010. METHODS: Kentucky Cabinet for Health and Family Services, Department for Behavioral Health Developmental and Intellectual Disabilities (BHDID) conducted a survey to evaluate consumers' satisfaction with services delivered at the CMHCs in Kentucky. The survey was administered at outpatient clinics operated by CMHCs. The validity and reliability of the survey were reviewed and a logistic regression model was developed using respondents' characteristics and their responses about several aspects of services. RESULTS: During the fiscal year 2010 (7/1/2009 ϳ 6/30/2010), 117,526 adult patients visited Kentucky CMHCs and 7,029 of them participated in the survey, resulting in a 5.98% penetration rate. Logistic regression analyses show that positive perceptions of access, quality and participation in treatment planning significantly increase positive responses for general satisfaction by 21%, 27% and 5%, respectively. (dy/dx ϭ 0.21, 0.27 and 0.05, pϽ0.05) Females are shown to be more likely to respond positively on general satisfaction (dy/dx ϭ 0.01, pϽ0.05). Age, race and regional characteristics (rural/urban) were not significantly related to responses to general satisfaction at the 95% confidence level. CONCLUSIONS: Responses to general satisfaction are more associated with responses to other domains than respondents' demographic characteristics. More specifically, the domains of access, quality, and participation in treatment planning are stronger predictors of a positive response on the "general satisfaction" question, suggesting that more attention to those domains of service could positively influence mental health care recipients' responses regarding general satisfaction.
PMH48
VALIDATION OF PSPSQ MEASURING PATIENT SATISFACTION WITH PSYCHIATRIC PHARMACY SERVICES
Sakharkar PR, Luu HA, Shankar GS, Law AV College of Pharmacy, Western University of Health Sciences, Pomona, CA, USA OBJECTIVES: To assess psychometric properties of the Patient Satisfaction with Pharmacist Services Questionnaire (PSPSQ) in a pharmacist-managed outpatient psychiatric care clinic. METHODS: This descriptive, cross-sectional study was conducted at a pharmacist-managed psychiatric care clinic in a behavioral healthcare facility in Southern California between Nov. 2011 and Jan. 2012. Patients were included if they were Ն18 years of age and able to read English. PSPSQ consists of 22 items assessed on a four point Likert scale, and hypothesized to have three domains: patient-pharmacist relationship, quality of care and overall satisfaction. This study was approved by the Institutional Review Board for exempt status. PSPSQ has been previously tested for face and content validity and is being validated in other pharmacist managed Disease State Management clinics. Data collected following patients' visit were analyzed descriptively. Correlations were examined between age, gender, education, insurance status and patient satisfaction. Scale reliability was assessed using Cronbach's alpha and construct validity using factor analysis. RESULTS: Thirty-five participants completed the survey. Mean age of participants was 41 years, 54% were male, 37.9% were Caucasian and Hispanic each, 81% had some college education, and 80% were covered by private health insurance. Cronbach's alpha of the tool was 0.971 indicating very high reliability.
After excluding two items, factor analysis yielded 19 items loading on three factors accounting for 79.6% of the variance. Only one item loaded on a factor different than hypothesized. The overall mean score of 3.5/4 indicated patient satisfaction with the pharmacist services they received. Patients with private insurance showed greater satisfaction compared to others (pϽ0.05). CONCLUSIONS: Our results suggest that the PSPSQ can serve as a reliable and valid tool for measuring patient satisfaction with pharmacist clinical services in a community/ambulatory care setting. Further research is needed to confirm its utility in other pharmacy practice settings. 
PMH49
SEVERITY OF AUTISM SPECTRUM DISORDERS: EFFECT ON CAREGIVER BURDEN AND SATISFACTION WITH SCHOOL DISTRICT SERVICES
OBJECTIVES:
To assess the impact of severity of autism spectrum disorders (ASD) on caregiver burden and satisfaction with school district services. METHODS: Survey data was collected from 301 primary caregivers of children with ASD. Caregiver burden was measured using the Caregiver Strain Questionnaire (CGSQ) and ASD severity in children was measured using the Childhood Autism Rating Scale-Parent version (CARS-P) for functional impairments and Developmental Behavior Checklist-Parent version (DBC-P24) for behavior problems. Children with ASD were classified into high and low severity subgroups based on the scores received on CARS-P and DBC-P24, respectively. One-way analysis of variance (ANOVA) was performed to assess differences in caregiver burden scores and satisfaction with seven types of school district services between high and low severity subgroups. One-way AN-COVA was performed to determine the mediating effect of caregiver burden between ASD severity and satisfaction with school district services. RESULTS: An overall significant effect on caregiver burden scores was observed for both behavior problems (F (1,299) ϭ55.4, pՅ0.001) and functional impairments (F (1,299) ϭ 42.5, pՅ0.001) sub-groups. Higher scores were reported for the high behavior problems (Meanϭ8.3, S.Eϭ0.13) and the high functional impairments groups (Meanϭ 8.4, S.Eϭ0.15) . Satisfaction with all school district services except for occupational therapy differed significantly between the severity sub-groups. Caregivers of children with ASD in high behavior problems and high functional impairments groups reported lower satisfaction with services. The ANCOVA, however, showed no significant differences in service satisfaction between the severity sub-groups suggesting a mediating role of caregiver burden. CONCLUSIONS: Severity of a child's ASD as defined by a combination of the extent of functional impairments and behavior problems was found to be associated with higher caregiver burden and greater dissatisfaction with services. Clinical diagnosis of ASD severity alone may not predict the extent of unmet school service needs.
